Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial

The Lancet Infectious Diseases · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles